BeiGene

China's largest global biotech company focused on innovative oncology medicines

公司概况

BeiGene is a global biotechnology company headquartered in China that is focused on developing innovative and affordable medicines for cancer patients worldwide. The company's BTK inhibitor Brukinsa has become one of the best-selling cancer drugs globally, and BeiGene has built a commercial presence in over 40 countries. BeiGene represents China's most successful biotech globalization story.

行业

OncologyImmunologyHematology

主要市场

ChinaUSEuropeGlobal

为什么关注这家公司

BeiGene has shattered the perception that Chinese biotech companies cannot compete globally, with Brukinsa becoming a blockbuster drug in the US and European markets.

核心关注领域

OncologyHematologyImmunologyGlobal Commercialization

同行业公司

查看全部

Biocon

1 信号

India's largest biopharmaceutical company and global biosimilars leader

Bangalore, India

Celltrion

0 信号

South Korea's leading biosimilar manufacturer challenging global pharma giants

Incheon, South Korea

Daiichi Sankyo

0 信号

Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)

Tokyo, Japan

Doctor Anywhere

0 信号

Southeast Asia's leading omnichannel healthcare platform

Singapore

Halodoc

1 信号

Indonesia's leading telehealth and health-tech platform

Jakarta, Indonesia

Healius

0 信号

Australia's second-largest private pathology and imaging provider

Sydney, Australia

信号活动概览

0本月

1近 30 天

1总计

信号时间线

1 条

2026年2月

监管官方Feb 12

百济神州 PD-1 抑制剂替雷利珠单抗在日本获批，挑战全球制药巨头

百济神州的抗 PD-1 抗体替雷利珠单抗获得日本厚生劳动省批准，用于治疗非小细胞肺癌。

订阅 BeiGene 信号简报

当该公司有新信号时，立即收到通知。